Novartis announces updated analysis from Phase III NATALEE trial

In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqal added to endocrine therapy shows a deepening benefit beyond the three-year treatment period, reducing the risk of recurrence by 28.5%, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer. This invasive disease-free survival benefit was also consistent across all pre-specified patient subgroups, including those with node-negative disease. Late-breaking data from this four-year post-hoc analysis will be presented today at the European Society for Medical Oncology, ESMO, Congress 2024. Results were also consistent across secondary efficacy endpoints, including distant disease-free survival, with a trend for improvement in overall survival